MedTrace Logo

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

NCT00468182 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2015-05-07

No results posted yet for this study

Summary

The purpose of this study is to determine whether interferon-beta impairs the ability of plasmacytoid dendritic cells to promote pathogenic immune responses in patients with multiple sclerosis.

Conditions

Interventions

DRUG

Interferon-beta 1b (Betaseron)

Treatment of patients with FDA-approved Rx

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Rutgers, The State University of New Jersey

    lead OTHER

Principal Investigators

  • Konstantin Balashov, M.D., Ph.D. · Rutgers Robert Wood Johnson Medical School

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00468182 on ClinicalTrials.gov